GPC
SGNT

Glacier Peak Capital’s SAGENT PHARMACEUTICALS INC COM STK (DE) SGNT Stock Holding History

Glacier Peak Capital’s Portfolio SGNT Stock Details SGNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-53,469
Closed -$651K – 52
2016
Q1 		$651K Buy
53,469
+3,469
+7% +$48.6K 0.56% 32
2015
Q4 		$796K Buy
50,000
+29,246
+141% +$460K 0.51% 49
2015
Q3 		$318K Hold
20,754
– – 0.18% 50
2015
Q2 		$505K Buy
+20,754
New +$497K 0.25% 58

Other funds holding SGNT

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Penn Capital Management Philadelphia, Pennsylvania $1.29B AUM 53.44% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
NIMC
NWQ Investment Management Company Los Angeles, California $2.22B AUM 6.84% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Glacier Peak Capital's SGNT Position: Q2 2016 in Review

Glacier Peak Capital sold out of SAGENT PHARMACEUTICALS INC COM STK (DE) (SGNT) in Q2 2016, closing a stake of 53,469 shares — an estimated $651K sold.

Glacier Peak Capital first reported a position in SGNT in Q2 2015 and held it in 4 quarters. The position peaked at $796K in Q4 2015. 128 funds tracked by Wall St. Rank hold SGNT as of Q2 2016.

  • Glacier Peak Capital reported no remaining SAGENT PHARMACEUTICALS INC COM STK (DE) position as of Q2 2016 after selling out during the quarter.
  • Glacier Peak Capital sold 53,469 SAGENT PHARMACEUTICALS INC COM STK (DE) shares in Q2 2016, an estimated $651K.
  • Glacier Peak Capital first reported a position in SAGENT PHARMACEUTICALS INC COM STK (DE) in Q2 2015 and held it in 4 quarters.
  • Glacier Peak Capital's SAGENT PHARMACEUTICALS INC COM STK (DE) position peaked at $796K in Q4 2015.
  • 128 funds tracked by Wall St. Rank held SAGENT PHARMACEUTICALS INC COM STK (DE) as of Q2 2016.

Based on Glacier Peak Capital's 13F filing for Q2 2016, filed 12 Aug 2016.